A phase 2 trial of sotatercept targeting the TGF-β pathway in other forms of PAH recently completed with promising initial data (NCT03496207), showing a significant reduction in pulmonary vascular resistance, and also an improvement in 6-min walk distance (143). This evidence concerns the gene TGFB1 and pulmonary arterial hypertension.